MPLT导演Robert Malenka在季度亏损和股票下跌的情况下出售股票。 MPLT director Robert Malenka sold shares amid quarterly loss and stock decline.

光疗法 (MPLT) 董事罗伯特·马伦卡于2026年1月29日以每股18.55美元的价格出售了21,262股股票,净利为394,410美元,并将其股权减少了5.41%至371,885股. Maplight Therapeutics (MPLT) Director Robert Malenka sold 21,262 shares on January 29, 2026, at $18.55 per share, netting $394,410 and reducing his stake by 5.41% to 371,885 shares. 该公司报告,每股季度损失37.18美元,未达到预期值。 The company reported a quarterly loss of $37.18 per share, missing expectations. 1月30日,库存关闭17.69美元,减少0.89美元,超过平均水平。 On January 30, the stock closed at $17.69, down $0.89, with above-average volume. 市值为8.026亿美元，共识分析师评级为“中度买入”，目标为31.00美元。 The market cap is $802.6 million, and the consensus analyst rating is "Moderate Buy" with a $31.00 target. 该公司正在研发中枢神经系统紊乱的治疗方法。 The firm is developing treatments for central nervous system disorders.